Home / Available CME / EU Pharmacokinetics

EU Pharmacokinetics

EU_Pharmaco_Static_Bannerv2

Please Click Here to See Important Information Regarding the Application Submission with The European Union of Medical Specialists (UEMS)

About the Program

Program Overview
Target Audience
Learning Objectives
Faculty
Accreditation Statement
Credit Designation
Disclosure of Conflicts of Interest
Disclosure of Unlabeled Use
Instructions for Participation and Credit

Program Overview

This one-hour, Internet symposium will review and discuss the key studies on assessing and managing pharmacokinetics and important potential drug interactions in HIV-positive patients. This symposium will feature an interview of David Back, PhD, one of the leading experts on pharmacology in HIV, by Calvin Cohen, MD, MS, Research Director of CRI New England and Clinical Instructor at Harvard Medical School.

This program is certified for CME credit for US physicians by the Postgraduate Institute for Medicine. This program is for health care providers who treat HIV-positive patients; there are no prerequisites.

Program Note: At the conclusion of the live program, an application will be submitted to the European Union of Medical Specialists (UEMS) for approval to provide direct EACCME accredited continuing medical education for European participants. Currently, participating non-US physicians can receive the specified number of AMA PRA Category 1 Credits specific to the program and have these converted to their national CME credit in their specific country, where applicable. Similarly, non-US health care providers other than physicians can receive a certificate of completion and use this to acquire national credit through their national continuing medical education board/association, where applicable. If you have any questions, please contact ViralEd at admin@viraled.com

Target Audience

This activity has been designed to meet the educational needs of physicians involved in the care of patients with HIV infection.

Learning Objectives

Following this program, participants will be able to:

Understand and apply important concepts and issues regarding pharmacokinetics and drug interactions in HIV patients;
Discuss important pharmacokinetic and drug interaction issues that can occur in HIV patients;
Use data regarding the assessment and management of pharmacokinetics and drug interactions to improve the overall health of HIV-positive patients;
Select HIV treatment regimens that maximize each patient's chance of long-term success and minimize the risk of adverse pharmacokinetic or drug interaction complications.

Release Date: July 9, 2010
Expiration Date: July 9, 2011

Estimated time to complete the Web Symposium: 1 hour

Media: Internet

Faculty

David J. Back, PhD
Professor of Pharmacology,
University of Liverpool
Liverpool, England

Calvin J. Cohen, MD, MS
Research Director, CRI New England,
Clinical Instructor, Harvard Medical School
Boston, Massachusetts

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and ViralEd, LLC. PIM is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) assesses conflicts of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The facultyreported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Dr. David Back:

Contracted Research: GlaxoSmithKline; Merck; Tibotec
Consulting Fees: ViiV; Boehringer Ingelheim; Merck; Bristol-Myers Squibb
Speakers' Bureau: Merck; Tibotec

Dr. Calvin Cohen:

Contracted Research: Bristol-Myers Squibb; Gilead; Merck & Co.; Pfizer; Tibotec
Consulting Fees: Bristol-Myers Squibb; Gilead; Merck & Co.; Pfizer; Tibotec
Speakers' Bureau: Bristol-Myers Squibb; Gilead; Merck & Co.; Tibotec

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

The following PIM planners and managers: Jan Hixon, RN, BSN, MS, Trace Hutchison, PharmD, Julia Kirkwood, RN, BSN, Samantha Mattiucci, PharmD and Jan Schultz, RN, MSN, CCMEP hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interest related to the content of these activities of any amount during the past 12 months.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), ViralEd, LLC, and Merck & Co., Inc. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, ViralEd, LLC, and Merck & Co., Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.